 Brigitte Frohnert
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 41 | 2023 | 3245 | 3.540 |
Why?
| | Islets of Langerhans | 17 | 2023 | 729 | 2.720 |
Why?
| | Autoimmunity | 21 | 2023 | 818 | 2.310 |
Why?
| | Autoantibodies | 26 | 2023 | 1354 | 1.470 |
Why?
| | Celiac Disease | 5 | 2022 | 264 | 0.980 |
Why?
| | Protein Carbonylation | 3 | 2015 | 51 | 0.920 |
Why?
| | Genetic Predisposition to Disease | 10 | 2023 | 2108 | 0.850 |
Why?
| | Insulins | 1 | 2023 | 32 | 0.830 |
Why?
| | Insulin Resistance | 6 | 2013 | 1077 | 0.820 |
Why?
| | Oxidative Stress | 3 | 2013 | 1085 | 0.810 |
Why?
| | Insulin Infusion Systems | 3 | 2023 | 296 | 0.730 |
Why?
| | Child, Preschool | 26 | 2023 | 9093 | 0.710 |
Why?
| | Adipocytes | 4 | 2013 | 189 | 0.680 |
Why?
| | Child | 38 | 2023 | 18407 | 0.640 |
Why?
| | Insulin | 9 | 2023 | 2082 | 0.640 |
Why?
| | Bone Density | 3 | 2020 | 432 | 0.620 |
Why?
| | HLA-D Antigens | 1 | 2017 | 34 | 0.580 |
Why?
| | Infant | 18 | 2023 | 7946 | 0.520 |
Why?
| | Infusions, Subcutaneous | 1 | 2015 | 19 | 0.510 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2013 | 151 | 0.500 |
Why?
| | Prospective Studies | 14 | 2023 | 6232 | 0.500 |
Why?
| | Disease Progression | 9 | 2023 | 2389 | 0.490 |
Why?
| | Equipment Failure | 1 | 2015 | 107 | 0.490 |
Why?
| | Hypoglycemic Agents | 4 | 2023 | 1006 | 0.480 |
Why?
| | Models, Genetic | 1 | 2017 | 566 | 0.470 |
Why?
| | Adolescent | 24 | 2023 | 17864 | 0.460 |
Why?
| | Genotype | 7 | 2022 | 1780 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2020 | 1901 | 0.420 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 139 | 0.420 |
Why?
| | Biomarkers | 5 | 2023 | 3419 | 0.410 |
Why?
| | Humans | 56 | 2023 | 115044 | 0.410 |
Why?
| | Adiposity | 3 | 2013 | 466 | 0.400 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 13 | 0.380 |
Why?
| | Obesity | 3 | 2013 | 2524 | 0.370 |
Why?
| | Fasting | 2 | 2010 | 242 | 0.370 |
Why?
| | Metabolomics | 1 | 2015 | 527 | 0.370 |
Why?
| | Blood Glucose | 3 | 2023 | 1821 | 0.340 |
Why?
| | Case-Control Studies | 9 | 2023 | 3015 | 0.340 |
Why?
| | Male | 33 | 2022 | 55731 | 0.330 |
Why?
| | Female | 34 | 2022 | 59614 | 0.330 |
Why?
| | Blood Glucose Self-Monitoring | 3 | 2023 | 497 | 0.320 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2019 | 46 | 0.310 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 957 | 0.290 |
Why?
| | Mitochondria | 1 | 2013 | 750 | 0.290 |
Why?
| | Inflammation | 2 | 2017 | 2485 | 0.280 |
Why?
| | Macrophages | 1 | 2013 | 1267 | 0.270 |
Why?
| | DNA Methylation | 2 | 2020 | 496 | 0.260 |
Why?
| | Cardiovascular Diseases | 2 | 2013 | 1729 | 0.240 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 814 | 0.240 |
Why?
| | Oxylipins | 2 | 2023 | 27 | 0.240 |
Why?
| | HLA-DR4 Antigen | 3 | 2021 | 76 | 0.230 |
Why?
| | HLA-DR3 Antigen | 3 | 2021 | 79 | 0.230 |
Why?
| | Membrane Transport Proteins | 3 | 1999 | 138 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2015 | 2098 | 0.220 |
Why?
| | Carrier Proteins | 4 | 2000 | 696 | 0.220 |
Why?
| | GTP-Binding Proteins | 2 | 2021 | 141 | 0.210 |
Why?
| | Transglutaminases | 2 | 2021 | 142 | 0.210 |
Why?
| | Technology | 1 | 2023 | 79 | 0.210 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 220 | 0.210 |
Why?
| | Longitudinal Studies | 5 | 2022 | 2389 | 0.200 |
Why?
| | Glutathione Transferase | 2 | 2013 | 95 | 0.200 |
Why?
| | Growth Charts | 1 | 2022 | 14 | 0.200 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 344 | 0.200 |
Why?
| | Body Height | 1 | 2022 | 180 | 0.190 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2021 | 28 | 0.180 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 33 | 0.180 |
Why?
| | Prediabetic State | 1 | 2023 | 224 | 0.180 |
Why?
| | Glutamate Decarboxylase | 4 | 2022 | 160 | 0.180 |
Why?
| | Mannose | 1 | 2019 | 21 | 0.170 |
Why?
| | Risk Factors | 9 | 2023 | 8643 | 0.170 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 81 | 0.170 |
Why?
| | Inservice Training | 1 | 2020 | 107 | 0.170 |
Why?
| | Young Adult | 6 | 2020 | 10498 | 0.170 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 318 | 0.160 |
Why?
| | Glucose Intolerance | 2 | 2010 | 137 | 0.160 |
Why?
| | Butyrates | 1 | 2019 | 53 | 0.160 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 4411 | 0.160 |
Why?
| | Ascorbic Acid | 1 | 2019 | 110 | 0.160 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 56 | 0.160 |
Why?
| | Membrane Proteins | 3 | 1999 | 1019 | 0.160 |
Why?
| | Fibrinogen | 1 | 2019 | 155 | 0.160 |
Why?
| | Fatty Acids | 3 | 2000 | 385 | 0.160 |
Why?
| | Mentors | 1 | 2020 | 158 | 0.160 |
Why?
| | Mentoring | 1 | 2020 | 101 | 0.150 |
Why?
| | Cohort Studies | 5 | 2022 | 4904 | 0.150 |
Why?
| | Mass Spectrometry | 1 | 2021 | 634 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 251 | 0.150 |
Why?
| | Mammals | 1 | 2000 | 245 | 0.150 |
Why?
| | Thiazolidinediones | 1 | 1999 | 143 | 0.150 |
Why?
| | Triglycerides | 1 | 2000 | 471 | 0.150 |
Why?
| | Discriminant Analysis | 1 | 2017 | 38 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2022 | 5041 | 0.150 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 223 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 193 | 0.140 |
Why?
| | Models, Statistical | 1 | 2021 | 602 | 0.140 |
Why?
| | Osteoporosis | 1 | 2020 | 225 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 381 | 0.140 |
Why?
| | Mass Screening | 2 | 2021 | 1012 | 0.140 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 617 | 0.140 |
Why?
| | History, 21st Century | 1 | 2017 | 161 | 0.140 |
Why?
| | Family Health | 1 | 2017 | 194 | 0.130 |
Why?
| | HLA-DQ Antigens | 1 | 2017 | 177 | 0.130 |
Why?
| | Organelle Biogenesis | 1 | 2015 | 15 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2017 | 617 | 0.130 |
Why?
| | Proteomics | 1 | 2021 | 844 | 0.130 |
Why?
| | Age of Onset | 1 | 2017 | 449 | 0.130 |
Why?
| | Genetic Testing | 1 | 2018 | 380 | 0.130 |
Why?
| | Proteins | 1 | 2021 | 915 | 0.130 |
Why?
| | Subcutaneous Fat | 1 | 2015 | 71 | 0.130 |
Why?
| | Hypoglycemia | 1 | 2020 | 385 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2017 | 245 | 0.120 |
Why?
| | Intestinal Mucosa | 1 | 2000 | 528 | 0.120 |
Why?
| | Body Mass Index | 2 | 2013 | 1967 | 0.120 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1318 | 0.120 |
Why?
| | Gastric Bypass | 1 | 2015 | 93 | 0.120 |
Why?
| | Transcription Factors | 2 | 2015 | 1531 | 0.110 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 24 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 394 | 0.110 |
Why?
| | Age Factors | 3 | 2020 | 2894 | 0.110 |
Why?
| | Growth Disorders | 1 | 2013 | 78 | 0.110 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 105 | 0.110 |
Why?
| | Muscle Cells | 1 | 2013 | 42 | 0.110 |
Why?
| | Aldehydes | 1 | 2013 | 142 | 0.100 |
Why?
| | Models, Biological | 1 | 2019 | 1636 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2012 | 38 | 0.100 |
Why?
| | Glutathione | 1 | 2013 | 302 | 0.100 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 33 | 0.100 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2011 | 30 | 0.090 |
Why?
| | United States | 4 | 2022 | 12226 | 0.090 |
Why?
| | Intra-Abdominal Fat | 1 | 2011 | 83 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 131 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1715 | 0.090 |
Why?
| | Time Factors | 2 | 2017 | 6141 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 271 | 0.090 |
Why?
| | Survivors | 1 | 2012 | 410 | 0.080 |
Why?
| | Adult | 5 | 2015 | 30656 | 0.080 |
Why?
| | Glucose | 1 | 2013 | 900 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1138 | 0.080 |
Why?
| | Obesity, Morbid | 1 | 2011 | 198 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2015 | 2563 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 1812 | 0.080 |
Why?
| | Hyperglycemia | 1 | 2010 | 293 | 0.070 |
Why?
| | Overweight | 1 | 2011 | 474 | 0.070 |
Why?
| | Genetic Association Studies | 2 | 2020 | 344 | 0.070 |
Why?
| | Colorado | 3 | 2023 | 4089 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4420 | 0.070 |
Why?
| | Risk Assessment | 3 | 2020 | 2976 | 0.060 |
Why?
| | Fatty Acid Transport Proteins | 3 | 1999 | 18 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 906 | 0.060 |
Why?
| | Prognosis | 3 | 2018 | 3334 | 0.050 |
Why?
| | Mice | 3 | 2013 | 14927 | 0.050 |
Why?
| | Finland | 1 | 2022 | 69 | 0.050 |
Why?
| | Germany | 1 | 2022 | 85 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 138 | 0.050 |
Why?
| | Animals | 5 | 2013 | 31867 | 0.050 |
Why?
| | Perception | 1 | 2023 | 310 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 8 | 0.050 |
Why?
| | Linoleic Acid | 1 | 2021 | 38 | 0.050 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2021 | 58 | 0.050 |
Why?
| | Immunoglobulin D | 1 | 2021 | 27 | 0.050 |
Why?
| | Serologic Tests | 1 | 2021 | 49 | 0.050 |
Why?
| | Arachidonic Acid | 1 | 2021 | 117 | 0.050 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 69 | 0.050 |
Why?
| | Iodide Peroxidase | 1 | 2020 | 27 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 161 | 0.050 |
Why?
| | Markov Chains | 1 | 2021 | 114 | 0.050 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 45 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 75 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 96 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 56 | 0.040 |
Why?
| | Transfection | 2 | 1999 | 872 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 1999 | 11 | 0.040 |
Why?
| | Absorption | 1 | 2000 | 52 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 157 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 101 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 55 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 171 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 59 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 234 | 0.040 |
Why?
| | Diffusion | 1 | 2000 | 118 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 251 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 522 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 474 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 196 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 323 | 0.040 |
Why?
| | Chromans | 1 | 1999 | 21 | 0.040 |
Why?
| | Oleic Acid | 1 | 1999 | 30 | 0.040 |
Why?
| | Retinoid X Receptors | 1 | 1999 | 39 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 218 | 0.040 |
Why?
| | Neoplasms | 1 | 2012 | 2106 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 140 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 1999 | 50 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 203 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 372 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 413 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 483 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 287 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 176 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 228 | 0.040 |
Why?
| | Thiazoles | 1 | 1999 | 110 | 0.040 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 81 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 181 | 0.040 |
Why?
| | Base Sequence | 2 | 1999 | 2119 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 236 | 0.040 |
Why?
| | Tretinoin | 1 | 1999 | 124 | 0.040 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 212 | 0.040 |
Why?
| | Universities | 1 | 2020 | 339 | 0.040 |
Why?
| | Postmenopause | 1 | 2020 | 304 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 447 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 309 | 0.040 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 159 | 0.040 |
Why?
| | Social Media | 1 | 2020 | 133 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 416 | 0.040 |
Why?
| | Gestational Age | 1 | 2020 | 758 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 256 | 0.040 |
Why?
| | Pelvic Bones | 1 | 2020 | 127 | 0.040 |
Why?
| | Anxiety | 1 | 2023 | 845 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 544 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 2796 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 385 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 776 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 528 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2255 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 678 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2021 | 682 | 0.030 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2015 | 3 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1398 | 0.030 |
Why?
| | Up-Regulation | 1 | 1999 | 812 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 42 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 524 | 0.030 |
Why?
| | Parents | 1 | 2023 | 1190 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2015 | 53 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2018 | 363 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 2016 | 102 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.030 |
Why?
| | Risk | 1 | 2018 | 815 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2015 | 209 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1591 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1080 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 1721 | 0.030 |
Why?
| | Family | 1 | 2018 | 591 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2799 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 220 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1435 | 0.030 |
Why?
| | DNA | 1 | 1999 | 1352 | 0.030 |
Why?
| | Middle Aged | 3 | 2020 | 26827 | 0.030 |
Why?
| | Physicians | 1 | 2020 | 772 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1321 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 181 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1999 | 1700 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 455 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2318 | 0.020 |
Why?
| | Minnesota | 1 | 2010 | 134 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 1843 | 0.020 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2009 | 141 | 0.020 |
Why?
| | Fatty Liver | 1 | 2009 | 217 | 0.020 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 324 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 517 | 0.020 |
Why?
| | Aged | 1 | 2020 | 19119 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1999 | 35 | 0.010 |
Why?
| | COS Cells | 1 | 1999 | 175 | 0.010 |
Why?
| | Introns | 1 | 1998 | 227 | 0.010 |
Why?
| | Exons | 1 | 1998 | 301 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 310 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 524 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1998 | 490 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1998 | 188 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 728 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1133 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 12547 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 1898 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1998 | 1317 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2329 | 0.010 |
Why?
|
|
Frohnert's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|